drugset / Trial / NCT05251181

A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent

NCT05251181 ↗

Phase 3 Not yet recruiting 430 enrolled Pharmazz, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This protocol is designed to develop a novel first-in-class treatment for use in critical care and life-threatening condition of hypovolemic shock with unmet need and is of national interest. Shock is a life-threatening condition of circulatory failure. It is a state of cellular and tissue hypoxia due to reduced oxygen delivery and/or increased oxygen consumption or inadequate oxygen utilization. Shock most commonly occurs when there is circulatory failure leading to reduced tissue perfusion. There are four types of shock: distributive, cardiogenic, hypovolemic, and obstructive. However, these are not exclusive, and many patients with circulatory failure have a combination of more than one form of shock (multifactorial shock).

Timeline

Start
2026-02
Primary completion
2026-10
Completion
2027-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Centhaquine Unknown 0.01 mg/kg Intravenous

Indications

No indication recorded.